Mark Lebwohl News Today

Experts discuss the plethora of treatment options for psoriasis, including topicals, oral therapies, phototherapy, and biologics.

Both an approved anti-IL-17 therapy and an experimental oral anti-IL-23 therapy appeared to achieve relatively undiminished rates of psoriasis control in extension studies.

There are many drugs that have been around for years and others with strong data awaiting FDA approval that are beneficial in treating conditions like atopic dermatitis and alopecia areata, said James Q. Del Rosso, DO.

Results from the POETYK PSO-1 trial showed significantly greater improvements in patients receiving deucravacitinib compared with placebo or apremilast.

A panel hosted at Fall Clinical Dermatology 2023 highlighted how dermatologists can help to address acne and psoriasis in their patients.

Bimekizumab is a novel, humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-7A and IL-17F, which are key cytokines driving inflammatory processes in plaque psoriasis.

The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

Bimekizumab is the first IL-17A and IL-17F inhibitor approved by the FDA for adults with psoriasis.

An analysis of patients with psoriasis, PsA, or axSpA show risk of MACE with ixekizumab is consistently low.

In research presented at the 2023 SDPA summer conference, new pharmacovigilance data over a 4-year span aligned with the established safety profile on brodalumab.